2023-08-08 07:25:44 ET
- Ironwood Pharmaceuticals press release ( NASDAQ: IRWD ): Q2 Non-GAAP EPS of -$6.71 misses by $6.96 .
- Revenue of $107.38M (+10.4% Y/Y) beats by $3.66M .
- Ironwood is increasing its 2023 U.S. LINZESS net sales and total revenue growth guidance and updating its adjusted EBITDA financial guidance. U.S. LINZESS Net Sales Growth of 6% to 8%; Total Revenue of $435 to $450 million vs. consensus of $428.53M; Adjusted EBITDA of ~ ($900) million.
For further details see:
Ironwood Pharmaceuticals reports mixed Q2 earnings; raises FY23 revenue outlook